Education Program
Description:
The anti-tumor immune response in lymphoma is typically compromised, exhausted or suppressed. Treatment strategies are being developed to manipulate the immune system and optimize immune function to generate a more effective anti-tumor immune response. In this session, we will discuss the fundamentals of immunotherapy for lymphoma, as well as strategies using checkpoint blockade, bispecific antibodies, novel drugs and cellular therapies to improve immune function.
Dr. Stephen Ansell will provide a general overview of the components that are necessary for an optimal anti-tumor immune response and highlight the immunological barriers to an adequate immune response that exist in patients with lymphoma.
Dr. Catherine Diefenbach will discuss the role of drugs in optimizing immune function in lymphoma. She will review clinical results with immune checkpoint blockade, bispecific antibodies, as well as small molecule inhibitors.
Dr. David Porter will review the use of cellular therapies in treating patients with lymphoma. He will discuss the biology, efficacy and side effects associated with cell-based approaches and the impact they are making on lymphoma management.
Chair:
Stephen M. Ansell, MD, PhD, Mayo Clinic
Disclosures:
Ansell: Regeneron: Research Funding; AI Therapeutics: Research Funding; ADC Therapeutics: Research Funding; Trillium: Research Funding; Affimed: Research Funding; Bristol Myers Squibb: Research Funding; Takeda: Research Funding; Seattle Genetics: Research Funding.
Panelists:
Stephen M. Ansell, MD, PhD, Mayo Clinic
,
Catherine Diefenbach, MD, New York University School of Medicine, NYU Cancer Institute
and
David L. Porter, MD, University of Pennsylvania
Disclosures:
Ansell: AI Therapeutics: Research Funding; Takeda: Research Funding; Seattle Genetics: Research Funding; Bristol Myers Squibb: Research Funding; Trillium: Research Funding; ADC Therapeutics: Research Funding; Regeneron: Research Funding; Affimed: Research Funding. Diefenbach: MEI: Research Funding; Bristol-Myers Squibb: Consultancy, Research Funding; Denovo: Research Funding; Genentech, Inc.: Consultancy, Research Funding; Incyte: Research Funding; LAM Therapeutics: Research Funding; Merck: Consultancy, Research Funding; Seattle Genetics: Consultancy, Research Funding; Millenium/Takeda: Research Funding; Trillium: Research Funding. Porter: Novartis: Honoraria, Other: Advisory board, Patents & Royalties: CAR T cells for CD19+ malignancies, Research Funding; Kite/Gilead: Other: Advisory board; Incyte: Other: Advisory board; Adicet bio: Other: Advisory board; Glenmark: Other: Advisory board; Genentech/Roche: Current equity holder in publicly-traded company, Other: Spouse employment (ended Sept 2020); her salary includes stock/options; Janssen: Other: Advisory board; National Marrow Donor Program: Membership on an entity's Board of Directors or advisory committees; American Board of Internal Medicine: Other: Member, exam writing committee (end date Oct 2019); Tmunity: Patents & Royalties.
The anti-tumor immune response in lymphoma is typically compromised, exhausted or suppressed. Treatment strategies are being developed to manipulate the immune system and optimize immune function to generate a more effective anti-tumor immune response. In this session, we will discuss the fundamentals of immunotherapy for lymphoma, as well as strategies using checkpoint blockade, bispecific antibodies, novel drugs and cellular therapies to improve immune function.
Dr. Stephen Ansell will provide a general overview of the components that are necessary for an optimal anti-tumor immune response and highlight the immunological barriers to an adequate immune response that exist in patients with lymphoma.
Dr. Catherine Diefenbach will discuss the role of drugs in optimizing immune function in lymphoma. She will review clinical results with immune checkpoint blockade, bispecific antibodies, as well as small molecule inhibitors.
Dr. David Porter will review the use of cellular therapies in treating patients with lymphoma. He will discuss the biology, efficacy and side effects associated with cell-based approaches and the impact they are making on lymphoma management.
denotes an abstract that is clinically relevant.
denotes that this is a ticketed session.